相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
Junshang Ge et al.
JOURNAL OF CANCER (2020)
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
Luca Cassetta et al.
CANCER CELL (2019)
Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells
Xiufeng Jiang et al.
CANCER CELL INTERNATIONAL (2019)
Effects and mechanisms of innate immune molecules on inhibiting nasopharyngeal carcinoma
Fang Xiong et al.
CHINESE MEDICAL JOURNAL (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Chien-Chun Steven Pai et al.
IMMUNITY (2019)
Natural killer group 2D receptor and its ligands in cancer immune escape
Shixin Duan et al.
MOLECULAR CANCER (2019)
TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Maria E. Rodriguez-Ruiz et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
Weili Xue et al.
ONCOTARGETS AND THERAPY (2019)
Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
Jun Zhao et al.
NATURE COMMUNICATIONS (2019)
The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
Gui-Zhen Wang et al.
NATURE COMMUNICATIONS (2019)
Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models
Steven A. Greenberg et al.
Oncotarget (2019)
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Deepak Mittal et al.
CANCER IMMUNOLOGY RESEARCH (2019)
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
Chu-Yu Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
Karin M. Knudson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release
Shu Lian et al.
EBIOMEDICINE (2019)
Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
Sha Zhou et al.
CANCERS (2019)
TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing
Lan Xiao et al.
CARCINOGENESIS (2019)
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Deepali Sawant et al.
NATURE IMMUNOLOGY (2019)
CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
Rajarsi Mandal et al.
SCIENCE (2019)
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
Jessica M. Konen et al.
CANCERS (2019)
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Heng-Huan Lee et al.
CANCER CELL (2019)
Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis
Ke Jin et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
PVT1 Promotes Cancer Progression via MicroRNAs
Wenxi Wang et al.
FRONTIERS IN ONCOLOGY (2019)
Neoantigen vaccine: an emerging tumor immunotherapy
Miao Peng et al.
MOLECULAR CANCER (2019)
Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-I Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report
Shanshan Yu et al.
ONCOTARGETS AND THERAPY (2019)
A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas
Gouji Toyokawa et al.
ANNALS OF THORACIC SURGERY (2019)
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response
Shilpak Chatterjee et al.
CLINICAL CANCER RESEARCH (2019)
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Kyung Hwan Kim et al.
CLINICAL CANCER RESEARCH (2019)
Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer
Eliana La Rocca et al.
MEDICAL ONCOLOGY (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
Aurelie Hanoteau et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
Shu Lian et al.
SCIENTIFIC REPORTS (2019)
PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection
Xintong Lyu et al.
JOURNAL OF CANCER (2019)
The role of Wnt signaling pathway in tumor metabolic reprogramming
Yongzhen Mo et al.
JOURNAL OF CANCER (2019)
Predicting tumour response to anti-PD-1 immunotherapy with computational modelling
Damijan Valentinuzzi et al.
PHYSICS IN MEDICINE AND BIOLOGY (2019)
Herpesvirus acts with the cytoskeleton and promotes cancer progression
Yingfen Wu et al.
JOURNAL OF CANCER (2019)
GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma
Chunmei Fan et al.
JOURNAL OF CANCER (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Proteomic Analysis of the Molecular Mechanism of Lovastatin Inhibiting the Growth of Nasopharyngeal Carcinoma Cells
Yongzhen Mo et al.
JOURNAL OF CANCER (2019)
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
Susanne Horn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
Susanne Horn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer
Jonas Janikovits et al.
ONCOIMMUNOLOGY (2018)
Up-regulation of DUSP5 and DUSP6 by gonadotropin-releasing hormone in cultured hypothalamic neurons, GT1-7 cells
Teruyuki Higa et al.
BIOMEDICAL RESEARCH-TOKYO (2018)
Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
T. Finazzi et al.
BMC CANCER (2018)
Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma
Karen C. Galvin et al.
CANCER LETTERS (2018)
Interleukin-35 Suppresses the Antitumor Activity of T Cells in Patients with Non-Small Cell Lung Cancer
Hong-Min Wang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky et al.
CLINICAL CANCER RESEARCH (2018)
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer
Alona Zer et al.
CLINICAL LUNG CANCER (2018)
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
Jooeun Bae et al.
LEUKEMIA (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
Qi Lai et al.
ONCOGENE (2018)
Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta 4/SNAI1/SIRT3 signaling pathway
Shaojia Wang et al.
ONCOGENE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer
A. Marijne Heeren et al.
FRONTIERS IN IMMUNOLOGY (2018)
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
Elizabeth Ahern et al.
ONCOIMMUNOLOGY (2018)
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Na Luo et al.
ONCOIMMUNOLOGY (2018)
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors
Mario M. Soldevilla et al.
ONCOIMMUNOLOGY (2018)
Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
Sang-Soo Kim et al.
ONCOIMMUNOLOGY (2018)
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial
Maud Toulmonde et al.
JAMA ONCOLOGY (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Monitoring immune checkpoint regulators as Predictive Biomarkers in hepatocellular carcinoma
Ritu Shrestha et al.
FRONTIERS IN ONCOLOGY (2018)
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
Shan Xie et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing
Chaofeng Tu et al.
CARCINOGENESIS (2018)
Notch signaling pathway suppresses CD8+ T cells activity in patients with lung adenocarcinoma
Shuo Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab
Hisako Okuhira et al.
BIOSCIENCE TRENDS (2018)
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
Haibo Mou et al.
BMC CANCER (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Effects of tumor metabolic microenvironment on regulatory T cells
Yi-an Wang et al.
MOLECULAR CANCER (2018)
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Lin-CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade
Catherine T. Flores et al.
NATURE COMMUNICATIONS (2018)
Application of atomic force microscopy in cancer research
Xiangying Deng et al.
JOURNAL OF NANOBIOTECHNOLOGY (2018)
Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy
Dengbo Ji et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Acquired resistance to immunotherapy in MMR-D pancreatic cancer
Zishuo Ian Hu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy
Jingjing Duan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Blockade of CCL2 enhances immunotherapeutic effect of anti-PDl in lung cancer
Yue Wang et al.
JOURNAL OF BONE ONCOLOGY (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer
Glenn J. Hanna et al.
JCI INSIGHT (2018)
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie-Nicole Theodoraki et al.
CLINICAL CANCER RESEARCH (2018)
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas B. Johnson et al.
JCI INSIGHT (2018)
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
T. Kordbacheh et al.
ANNALS OF ONCOLOGY (2018)
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice
Efimia Boutsikou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'
Raul S. Gonzalez et al.
HISTOPATHOLOGY (2017)
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
Jamaal A. Rehman et al.
MODERN PATHOLOGY (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
Gulidanna Shayan et al.
ONCOIMMUNOLOGY (2017)
Analysis of non-small cell lung cancer microenvironment indicates preponderance of T cell exhaustion marker expression
Hui Zhou et al.
EXPERIMENTAL CELL RESEARCH (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
Esra A. Akbay et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens
Chaofeng Tu et al.
JOURNAL OF VIROLOGY (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
Gustavo Schvartsman et al.
LUNG CANCER (2017)
Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies Three case reports
Chieh-Sheng Lu et al.
MEDICINE (2017)
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma
Carlos A. Morales-Betanzos et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Florie Bertrand et al.
NATURE COMMUNICATIONS (2017)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker et al.
NATURE COMMUNICATIONS (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Daniel Zingg et al.
CELL REPORTS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade
Dirk Zboralski et al.
CANCER IMMUNOLOGY RESEARCH (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
Florine A. a Eggink et al.
ONCOIMMUNOLOGY (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma
Guozhu Xie et al.
CANCER BIOLOGY & THERAPY (2017)
PD-1 deficiency protects experimental colitis via alteration of gut microbiota
Seong Jeong Park et al.
BMB REPORTS (2017)
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Simon J. Dovedi et al.
CLINICAL CANCER RESEARCH (2017)
Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma
Akira Shimizu et al.
JOURNAL OF GLOBAL ONCOLOGY (2017)
Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
Nicolas A. Giraldo et al.
CLINICAL CANCER RESEARCH (2017)
miR-142-5p regulates tumor cell PD-Ll expression and enhances anti-tumor immunity
Long Jia et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation
Michael Hettich et al.
CANCER RESEARCH (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Reversing T-cell Dysfunction and Exhaustion in Cancer
Hassane M. Zarour
CLINICAL CANCER RESEARCH (2016)
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C. Dudley et al.
CLINICAL CANCER RESEARCH (2016)
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
Jacquelyn Smith et al.
DIAGNOSTIC PATHOLOGY (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M. Mehnert et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer
Seiichi Ikeda et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Role of adenosine A2b receptor overexpression in tumor progression
Cesar Sepulveda et al.
LIFE SCIENCES (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The oncolytic peptide LTX-315 triggers immunogenic cell death
H. Zhou et al.
CELL DEATH & DISEASE (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
IDO1 is an Integral Mediator of Inflammatory Neovascularization
Arpita Mondal et al.
EBIOMEDICINE (2016)
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
Cesar Munoz-Fontela et al.
NATURE REVIEWS IMMUNOLOGY (2016)
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
K. Abiko et al.
BRITISH JOURNAL OF CANCER (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges
Feifei Teng et al.
CANCER LETTERS (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma
Jianwei Zhang et al.
MEDICAL ONCOLOGY (2015)
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme
Sang-Soo Kim et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt et al.
JAMA ONCOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Luisa Carbognin et al.
PLOS ONE (2015)
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Kevin C. Soares et al.
JOURNAL OF IMMUNOTHERAPY (2014)
A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival
Sang-Soo Kim et al.
ACS NANO (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Michael D. Iglesia et al.
CLINICAL CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Interferon Receptor Signaling in Malignancy: A Network of Cellular Pathways Defining Biological Outcomes
Eleanor N. Fish et al.
MOLECULAR CANCER RESEARCH (2014)
PTEN functions as a melanoma tumor suppressor by promoting host immune response
Y. Dong et al.
ONCOGENE (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Emerging patterns of somatic mutations in cancer
Ian R. Watson et al.
NATURE REVIEWS GENETICS (2013)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Modulation of Inflammatory Immune Reactions by Low-Dose Ionizing Radiation: Molecular Mechanisms and Clinical Application
F. Roedel et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Liesbeth C. W. Vredeveld et al.
GENES & DEVELOPMENT (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut
Shimpei Kawamoto et al.
SCIENCE (2012)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Epigenetic silencing of the PTEN gene in melanoma
Alireza Mirmohammadsadegh et al.
CANCER RESEARCH (2006)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
PTEN signaling pathways in melanoma
H Wu et al.
ONCOGENE (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation
XP Zhou et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies
A Birck et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
分享论文
